# Gilde IT Fund

> Gilde IT Fund is a VC fund in Utrecht backing Medical and Health Care. See 9 investments, round sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Utrecht, The Netherlands
- Total investments: 9
- Last investment: Apr 2011
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.gilde.nl

Gilde IT Fund is a VC fund in Utrecht focused on Medical and Health Care. Since its establishment in 1982, Gilde has invested in more than 250 companies. With offices in The Netherlands, France and Switzerland Gilde is one of the most prominent continental European private equity investors. Gilde operates through specialized investment funds for buy outs and life sciences. Funds under management exceed €2 billion.

## Contacts

5 contacts available for Gilde IT Fund. Shizune tracks 8 team members at Gilde IT Fund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/gilde-it-fund?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 22% |
| Health Care | 2 | 22% |
| Biotechnology | 2 | 22% |
| Telecommunications | 2 | 22% |
| Information Services | 2 | 22% |

24 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 33% |
| Series C | 2 | 22% |
| Series D | 2 | 22% |
| Seed | 1 | 11% |
| Funding Round | 1 | 11% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 33% |
| United Kingdom | 3 | 33% |
| Germany | 2 | 22% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Bas Glas | Investment Director, Partner | 0 | — |
| Charles Kotting | Investment Director | 0 | — |
| Daniel Winkelman | Investment Manager | 0 | — |
| Gerhard Nordemann | Managing Partner | 0 | — |
| Jakob Bieniaszewski | Business Analyst | 0 | — |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| SPR Therapeutics | SPRA Therapeutics is a medical device company that is commercializing pain treatments utilizing its proprietary peripheral nerve stimulation (PNS) products. They are developing a pipeline of neurostimulation pain therapies that will exploit the same physiologic mechanism of action, proprietary technology, and clinical approach. The first product tobe commercialized is the SMARTPATCHâ„¢ PNS System, which is a short-term, minimally invasive system that is simple to deliver and can be used for up to 30 days to stimulate electrically a peripheral nerve to relieve pain. | $1.2M | Seed | Apr 26, 2011 |  |
| Chroma Therapeutics | Chroma Therapeutics is a privately-held biotechnology company focused on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. Chroma is the first company to systematically assemble intellectual property in chromatin biology and has established a strong network of academiccollaborators. Chroma aims to build substantial shareholder value through the creation of a broad and innovative product pipeline aimed at the treatment of high-prevalence cancers and inflammatory disorders. | $24.5M | Series D | Jun 23, 2009 |  |
| Jobpartners | Jobpartners - http://www.jobpartners.com provides software solutions for People Relationship Management. Covering the employee lifecycle through selection, talent and performance management, through enterprise social networking, to compensation management and appraisals. The company raising VC for the first time in 2000, and to datehas attracted over £35 million of financing. Today, Jobpartners has a strong position in the European marketplace as well as customers in North America and across the rest of the world. | $12.1M | Series C | Apr 01, 2008 |  |
| Pieris | Pieris Pharmaceuticals is a clinical-stage biotechnology company that develops drugs to fight cancer, severe asthma, anemia, and other medical conditions with unmet medical needs. The company applies its proprietary Anticalin® technology to the drug development processes. Pieris Pharmaceuticals was founded in 2001 and is based in Freising,Bayern. | $6.4M | Series B | Nov 01, 2006 |  |
| Cambridge Broadband Networks | Cambridge Broadband designs wireless back-haul and access provisions that improve telecommunication network capacity and efficiency under increasing mobile data growth. The company's wireless back-haul and access provisions offers carrier-class, point-to-multipurpose broadband wireless access equipment, enabling telecom and mobile operators toaccelerate customers' return on investment. | $15.3M | Series C | May 11, 2004 |  |
| LaserComm | Lasercomm Inc was founded in 1998. The company's line of business includes providing telephone voice and data communications services.LaserComm is a privately held Israeli company. The company has developed a technology which established the foundation of a new breed of photonic components and modules for fiber optic networks. Based on itscore competence, LaserComm aims to break new grounds in the field of dispersion management. The company develops products specifically designed to increase bandwidth, improve reliability, and reduce the cost of services provided by long-haul and ultra long-haul carriers. | $21M | Series D | Feb 15, 2002 |  |
| Cambridge Broadband Networks | Cambridge Broadband designs wireless back-haul and access provisions that improve telecommunication network capacity and efficiency under increasing mobile data growth. The company's wireless back-haul and access provisions offers carrier-class, point-to-multipurpose broadband wireless access equipment, enabling telecom and mobile operators toaccelerate customers' return on investment. | $16.5M | Series B | Jun 01, 2001 |  |
| WorldStreet | WorldStreet Corp., a developer of collaborative commerce solutions for the financial industry. | $30M |  | Jun 21, 2000 |  |
| PolyTrax Information Technology | PolyTrax Information Technology AG is a logistics and supply chain company based out of 3 Danziger Straße, RO, BY, Germany. | $7.5M | Series B | May 04, 2000 |  |

9 of 9 investments shown.

## Co-investors
- [Techno Venture Management](https://shizune.co/investors/profile/tvm-techno-venture-management) — VC Fund, 3 deals together
- [Amadeus Capital Partners](https://shizune.co/investors/profile/amadeus-capital-partners) — VC Fund, 2 deals together
- Latin Rim — VC Fund, 2 deals together
- [AAC Capital Partners](https://shizune.co/investors/profile/aac-capital-partners) — VC Fund, 1 deal together
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 1 deal together
- [ABS Ventures](https://shizune.co/investors/profile/abs-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Gilde IT Fund invest in?

Gilde IT Fund invests primarily in Medical, Health Care and Biotechnology startups, most often at Series B and Series C stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Gilde IT Fund?

Public channels for Gilde IT Fund include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Gilde IT Fund?

The team at Gilde IT Fund includes Bas Glas (Investment Director, Partner), Charles Kotting (Investment Director) and Daniel Winkelman (Investment Manager), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co